



Clinical trial results:

Randomized Phase II Study of CABAZITAXEL versus METHOTREXATE in patients with recurrent or metastatic squamous cell carcinoma of the head and neck previously treated with platinum-based therapy

Summary

EudraCT number	2011-001938-42
Trial protocol	BE
Global end of trial date	03 November 2014

Results information

Result version number	v1 (current)
This version publication date	10 March 2021
First version publication date	10 March 2021

Trial information

Trial identification

Sponsor protocol code	UCL-ONCO2011-01
-----------------------	-----------------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01528163
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Cliniques universitaires Saint-Luc
Sponsor organisation address	Avenue Hippocrate, 10, Brussels, Belgium, 1200
Public contact	Centre du Cancer, Cliniques universitaires Saint-Luc, 0032 27645457, jean-pascal.machiels@uclouvain.be
Scientific contact	Centre du Cancer, Cliniques universitaires Saint-Luc, 0032 27645457, jean-pascal.machiels@uclouvain.be

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	26 January 2015
Is this the analysis of the primary completion data?	Yes
Primary completion date	03 November 2014
Global end of trial reached?	Yes
Global end of trial date	03 November 2014
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

Determine the efficacy of cabazitaxel in patients with head and neck cancer in terms of progression-free survival rate at 18 weeks (defined as the proportion of patients alive and free of progression at 18 weeks)

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonisation (ICH) Good Clinical Practice (GCP) regulations/guidelines, and country-specific national and local laws.

Safety was determined after each injection, after each assessment, after 3 cycles and every 9 weeks, depending on the course of the disease.

All observed or deliberate adverse events, regardless of the treatment group or suspected causal relationship with the investigational product, have been reported.

The investigator followed the outcome of any adverse event (clinical signs, laboratory or other values, etc) up to 28 days after the last administration. For adverse events causally related to the investigational product, investigator follow-up is necessary until the event or its sequelae are resolved or stabilized at a level acceptable to the investigator and the coordinator of the study.

Background therapy:

Cabazitaxel: from 20 mg/m² to 25 mg/m². Intravenous injection every three weeks.

Evidence for comparator:

Methotrexate: from 40 mg/m² (first cycle) to 50 mg/m². Intravenous injections every three weeks.

Actual start date of recruitment	24 January 2012
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Belgium: 99
Country: Number of subjects enrolled	Luxembourg: 2
Worldwide total number of subjects	101
EEA total number of subjects	101

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0

Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	84
From 65 to 84 years	17
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The subjects were recruited from 15 sites: 14 of which belong to the Member State (Belgium) and one site in Luxembourg.

Participants were included from January 12, 2012 to July 11, 2014.

Pre-assignment

Screening details:

Patients with incurable squamous cell carcinoma of the head and neck with progression after platinum-based therapy were randomly assigned to cabazitaxel or methotrexate. All the patients provided written informed consent.

Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Cabazitaxel

Arm description:

Patients receiving 20 mg/m² to 25 mg/m² Cabazitaxel intravenously every three weeks.

Arm type	Experimental
Investigational medicinal product name	Cabazitaxel
Investigational medicinal product code	XRP6258
Other name	Jevtana
Pharmaceutical forms	Concentrate for solution for injection/infusion
Routes of administration	Intravenous use

Dosage and administration details:

Cabazitaxel was continued until progressive disease, unacceptable toxicity, or a maxima of 10 cycles. The preparation of Cabazitaxel (XRP6258) infusion solution for administration requires the preparation of a premix solution at 60 mg/6 ml (nominal concentration). This must be done with a 13% m/m ethanol solution in water for injection (the "solvent") supplied with the cabazitaxel concentrate for solution for infusion ("preparation of the premix solution"). Then the premix solution must be diluted in an infusion vehicle ("preparation of the infusion solution") prior to administration.

Arm title	Methotrexate
------------------	--------------

Arm description:

From 40 mg/m² (first cycle) to 50 mg/m². Intravenous injections every three weeks.

Arm type	Active comparator
Investigational medicinal product name	Methotrexate
Investigational medicinal product code	SUB08856MIG
Other name	Emthexate
Pharmaceutical forms	Concentrate for solution for infusion
Routes of administration	Intravenous use

Dosage and administration details:

Patients will start on a dose of 40 mg/m² once weekly, and the dose increase to 50 mg/m² will be based on the investigator's clinical judgement.

Number of subjects in period 1	Cabazitaxel	Methotrexate
Started	53	48
Completed	53	48

Baseline characteristics

Reporting groups

Reporting group title	Cabazitaxel
Reporting group description: Patients receiving 20 mg/m2 to 25 mg/m2 Cabazitaxel intravenously every three weeks.	
Reporting group title	Methotrexate
Reporting group description: From 40 mg/m2 (first cycle) to 50 mg/m2. Intravenous injections every three weeks.	

Reporting group values	Cabazitaxel	Methotrexate	Total
Number of subjects	53	48	101
Age categorical Units: Subjects			
Adults (18-64 years)	44	40	84
From 65-84 years	9	8	17
Age continuous Units: years			
median	58	57.5	
full range (min-max)	46 to 80	41 to 78	-
Gender categorical Units: Subjects			
Female	10	7	17
Male	43	41	84

End points

End points reporting groups

Reporting group title	Cabazitaxel
Reporting group description:	
Patients receiving 20 mg/m2 to 25 mg/m2 Cabazitaxel intravenously every three weeks.	
Reporting group title	Methotrexate
Reporting group description:	
From 40 mg/m2 (first cycle) to 50 mg/m2. Intravenous injections every three weeks.	

Primary: Determine the efficacy of cabazitaxel in patients with head and neck cancer in terms of progression-free survival rate at 18 weeks

End point title	Determine the efficacy of cabazitaxel in patients with head and neck cancer in terms of progression-free survival rate at 18 weeks ^[1]
End point description:	
The primary endpoint was the progression-free survival rate (PFSR) at 18 weeks, defined as the proportion of patients alive and free of progression according to the RECIST at 18 weeks after treatment.	
End point type	Primary
End point timeframe:	
18 weeks	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: For the Primary Endpoint, descriptive statistics were performed and presented in proportion. The actual statistical analyses were performed for the secondary endpoints. The Kaplan-Meier method was used to estimate the median PFS and OS times.

End point values	Cabazitaxel	Methotrexate		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	53	48		
Units: Percentage				
number (confidence interval 95%)	13.2 (5 to 25)	8.3 (2 to 20)		

Statistical analyses

No statistical analyses for this end point

Secondary: Progression-free survival

End point title	Progression-free survival
End point description:	
End point type	Secondary
End point timeframe:	
PFS was defined as the time interval between the date of randomization and the date of disease progression or the date of death from any cause.	

End point values	Cabazitaxel	Methotrexate		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	53	48		
Units: Months				
median (inter-quartile range (Q1-Q3))	1.9 (1.6 to 2.1)	1.9 (1.5 to 2.1)		

Statistical analyses

Statistical analysis title	the median PFS
Comparison groups	Cabazitaxel v Methotrexate
Number of subjects included in analysis	101
Analysis specification	Pre-specified
Analysis type	other ^[2]
P-value	< 0.05
Method	The Kaplan-Meier method
Confidence interval	
level	95 %

Notes:

[2] - Noncomparative

Secondary: overall survival (OS)

End point title	overall survival (OS)
-----------------	-----------------------

End point description:

End point type	Secondary
----------------	-----------

End point timeframe:

OS was defined as the time interval between the date of randomization until death from any cause or until the date of the last follow-up visit.

End point values	Cabazitaxel	Methotrexate		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	53	48		
Units: Months				
median (inter-quartile range (Q1-Q3))	5 (3.6 to 6)	3.6 (2.7 to 6.2)		

Statistical analyses

Statistical analysis title	Overall survival
Comparison groups	Cabazitaxel v Methotrexate

Number of subjects included in analysis	101
Analysis specification	Pre-specified
Analysis type	other ^[3]
P-value	< 0.05
Method	The Kaplan-Meier method

Notes:

[3] - Noncomparative

Adverse events

Adverse events information

Timeframe for reporting adverse events:

All AEs observed regardless of treatment group or suspected cause-and-effect relationship with the investigational product were reported as soon as possible. Serious adverse events require immediate notification (within 24 hours).

Adverse event reporting additional description:

The investigator should follow up the outcome of any Adverse Events (up to 28 days post last administration). For adverse events with a causal relationship to the investigational product, follow-up by the investigator is required until the event or its sequelae resolve or stabilize at a level acceptable to the investigator and the study coordinator.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	CTCAE GRADE
Dictionary version	4.03

Reporting groups

Reporting group title	CABAZITAXEL
-----------------------	-------------

Reporting group description:

Intravenous injection every three weeks from 20 mg/m² to 25 mg/m²

Reporting group title	METHOTREXATE
-----------------------	--------------

Reporting group description:

Intravenous injections every three weeks from 40 mg / m² (first cycle) to 50 mg / m²

Serious adverse events	CABAZITAXEL	METHOTREXATE	
Total subjects affected by serious adverse events			
subjects affected / exposed	28 / 52 (53.85%)	17 / 45 (37.78%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Blood and lymphatic system disorders			
Febrile neutropenia			
subjects affected / exposed	9 / 52 (17.31%)	0 / 45 (0.00%)	
occurrences causally related to treatment / all	9 / 9	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenia			
subjects affected / exposed	25 / 52 (48.08%)	2 / 45 (4.44%)	
occurrences causally related to treatment / all	25 / 25	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			

subjects affected / exposed	2 / 52 (3.85%)	2 / 45 (4.44%)	
occurrences causally related to treatment / all	2 / 2	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Anemia			
subjects affected / exposed	1 / 52 (1.92%)	1 / 45 (2.22%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	CABAZITAXEL	METHOTREXATE	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	42 / 52 (80.77%)	41 / 45 (91.11%)	
Blood and lymphatic system disorders			
Neutropenia			
subjects affected / exposed	22 / 52 (42.31%)	5 / 45 (11.11%)	
occurrences (all)	1	1	
Thrombocytopenia			
subjects affected / exposed	20 / 52 (38.46%)	14 / 45 (31.11%)	
occurrences (all)	1	1	
Anemia			
subjects affected / exposed	42 / 52 (80.77%)	31 / 45 (68.89%)	
occurrences (all)	1	1	
General disorders and administration site conditions			
Weight loss			
subjects affected / exposed	3 / 52 (5.77%)	2 / 45 (4.44%)	
occurrences (all)	1	1	
Fatigue			
subjects affected / exposed	9 / 52 (17.31%)	3 / 45 (6.67%)	
occurrences (all)	1	1	
Gastrointestinal disorders			
Diarrhea			
subjects affected / exposed	7 / 52 (13.46%)	2 / 45 (4.44%)	
occurrences (all)	1	1	
Nausea			

subjects affected / exposed	4 / 52 (7.69%)	2 / 45 (4.44%)	
occurrences (all)	1	1	
Mucositis oral			
subjects affected / exposed	5 / 52 (9.62%)	5 / 45 (11.11%)	
occurrences (all)	1	1	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
07 February 2012	Amendment 1, version 1

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported